.svg){kind=small}
Apr-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Canna Clinicals has shown consistent performance in the Tincture & Sublingual category in New York, maintaining a steady rank of 9th place from January through April 2025. This stability indicates a strong foothold in this category, suggesting that their products resonate well with consumers in the state. Despite a dip in sales in February, the brand managed to recover and demonstrate an upward trend in subsequent months, closing April with a positive increase. This steady ranking amidst fluctuating sales suggests that while their consumer base remains loyal, external factors might influence monthly sales volumes.
In other states or provinces, Canna Clinicals did not make it into the top 30 brands in the Tincture & Sublingual category during these months, which could be seen as a challenge for their market penetration outside of New York. This absence from the rankings highlights potential areas for growth and expansion. It also suggests that while they have established a presence in New York, efforts to replicate this success in other markets might be necessary to enhance their overall brand performance and visibility. Understanding the factors that contribute to their success in New York could be key to improving their standings in other regions.
Competitive Landscape
In the competitive landscape of the Tincture & Sublingual category in New York, Canna Clinicals has maintained a consistent rank of 9th place from January to April 2025. Despite this stability, the brand faces significant competition from brands like Jaunty, which has consistently held a higher rank at 3rd place, and Mfny (Marijuana Farms New York), which improved its rank from 5th to 4th place by March. Notably, Canna Clinicals experienced a dip in sales in February, which could indicate challenges in market penetration or consumer retention. Meanwhile, competitors such as OMO - Open Minded Organics and High Falls Canna New York have shown more stable sales figures, suggesting that Canna Clinicals may need to explore strategies to enhance its market presence and drive sales growth in this competitive field.
Notable Products
In April 2025, the top-performing product from Canna Clinicals was the CBD/THC 1:10 Max Strength Tincture (100mg CBD, 1000mg THC, 30ml), maintaining its first-place rank for the fourth consecutive month with sales of 351 units. The CBD/THC Unwind Tincture (1050mg CBD, 90mg THC, 15ml) also held steady in second place, showing a slight increase in sales compared to previous months. The Max Strength Capsules 10-Pack (100mg CBD, 100mg THC) remained consistently in third place, demonstrating stable demand. A notable change was seen in the CBD/THC/CBG 1:1:1 Relief Complex Capsules 20-Pack, which rose to fourth place from an absence in March rankings, indicating a significant improvement in sales performance. The CBD/THC/CBN 1:1:1 Sleep Complex Capsules 20-Pack dropped out of the rankings this month, suggesting a shift in consumer preference or availability issues.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
